Medtronic (MDT) is back in focus after recent trading, with the share price at $101.34 and total return figures that span from the past week to the past 5 years drawing investor attention.

Measured over longer periods, the picture is steadier. Medtronic’s recent 1-month and 90-day share price returns, alongside a 1-year total shareholder return of 17.13% and 3-year total shareholder return of 36.56%, point to gradually building momentum rather than a sharp swing in sentiment.

If Medtronic’s move has you reassessing healthcare exposure, it could be a useful moment to scan healthcare stocks for other established names and fresh ideas in the sector.

With shares at $101.34, a value score of 4, a modest intrinsic discount of 1.70% and a 9.41% gap to the average analyst target, investors may ask whether Medtronic is still mispriced or if the market is already incorporating expectations of future growth.

Most Popular Narrative: 8.6% Undervalued

At $101.34, the most followed narrative puts Medtronic’s fair value at $110.87, describing today’s price as a modest discount rather than an outlier.

Medtronic's investments and breakthroughs in digital health technologies, robotics (Hugo), next-generation sensors, and AI-enabled ecosystems (e.g., spine AiBLE, advanced neuromodulation) align with industry-wide digital transformation and minimally invasive trends. These platforms are expected to expand procedure volumes and capture market share, supporting future top-line growth and higher-margin revenue streams.

Curious what earnings power and margin profile sit behind that valuation gap? The narrative focuses on steady expansion, richer profitability, and a future P/E that still remains below many peers.

Result: Fair Value of $110.87 (UNDERVALUED)

However, that steady expansion story still depends on a smooth Diabetes separation and successful new product ramp ups, as delays or weaker uptake could quickly reshape expectations.

Build Your Own Medtronic Narrative

If you see the numbers differently or prefer to work from your own data set, you can build a full Medtronic view in just a few minutes: Do it your way.

A great starting point for your Medtronic research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.

Ready for more investment ideas?

If Medtronic has sharpened your thinking, do not stop here; broaden your watchlist with a few focused screens that surface very different types of opportunities.

• Spot potential bargains early by zeroing in on these 880 undervalued stocks based on cash flows that might be pricing in more caution than their cash flows suggest.
• Tap into long term themes by scanning these 24 AI penny stocks that are tied to artificial intelligence and related technologies across multiple industries.
• Strengthen your income watchlist by filtering for these 12 dividend stocks with yields > 3% that could support a more regular stream of cash returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.